Drug intelligence / Profile preview

NRNT-012302

Development stage: Unknown
Lead developer: Neurentis
Modality: Small Molecules
Administration: Transdermal

Overview

NRNT-012302 (Quivara) is a broad-spectrum antidepressant developed by Neurentis for the treatment of treatment-resistant depression (TRD). It functions as a triple reuptake inhibitor, simultaneously targeting the dopamine, norepinephrine, and serotonin systems to modulate neurotransmitter levels. Formulated as a transdermal patch, NRNT-012302 is designed to provide continuous drug delivery and potentially minimize side effects associated with peak plasma concentrations of oral antidepressants. The program is currently advancing into Phase 3 clinical development.

Brand names: Quivara

Targets

NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on NRNT-012302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NRNT-012302.

Explore the full profile